Seres Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Operational Progress Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. DFTX
7. GOOGL
8. MU
9. HOOD
10. IBM

Go back to Seres Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Operational Progress Update

Seres Therapeutics (MCRB) Tops Q4 EPS by 9c

March 16, 2017 7:25 AM EDT

Seres Therapeutics (NASDAQ: MCRB) reported Q4 EPS of ($0.63), $0.09 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $3 million versus the consensus estimate of $2.85 million.

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

... More